Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
about
Recent advances in migraine therapyThe Neuropharmacology of Cluster Headache and other Trigeminal Autonomic CephalalgiasHeadache management: pharmacological approachesA randomized controlled trial of acupressure as an adjunctive therapy to sodium valproate on the prevention of chronic migraine with auraZhengtian Capsule versus flunarizine in patients with migraine: a multi-center, double-blind, double-dummy, randomized controlled, non-inferior clinical trial.Are migraineurs naturally born "well-hearted"?Risk of Stroke in Migraineurs Using Triptans. Associations with Age, Sex, Stroke Severity and Subtype.Stroke, Migraine and Triptans: From Bedside to Bench.Migraine and Stroke: What's the Link? What to Do?Drug safety in acute migraine treatment.Headaches of the elderly.The Diagnosis and Treatment of Fibromuscular Dysplasia: An Update for Cardiologists.High-flow oxygen therapy for treatment of acute migraine: A randomized crossover trial.Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study.Migraine as a risk factor for young patients with ischemic stroke: a case-control study.Migraine and risk of stroke and acute coronary syndrome in two case-control studies in the Danish populationMigraine and stroke.Statins for all: should patients who have migraine with aura be on a statin?Migraine and risk of cardiovascular diseases: Danish population based matched cohort study.OCT1 mediates hepatic uptake of sumatriptan and loss-of-functionOCT1polymorphisms affect sumatriptan pharmacokinetics
P2860
Q26743537-48C525D3-814F-42B4-82E3-42283EF537D3Q26786375-323A0220-563F-412F-BCAC-7E7F5E5961A7Q27316751-91E64598-776F-4D63-8151-369B909FD2C7Q33885922-1C90D3C1-1EED-4AFC-9A85-FFBA1331AFF3Q36130277-FA57D18D-7656-434D-B06F-3D273C95365CQ36766088-AA8EF2D8-72EF-4398-A49D-81DEBE10B761Q36869870-ED0D037C-8FDE-449D-8F87-D1C03A593E56Q36869995-B3FF291C-77DD-41A0-9A7B-75F4ED9F0980Q37693868-04C8E30E-8D4E-41B6-8DFF-CB9E66AF2B7BQ38378898-955C05C9-5283-4014-966E-5FDED401498DQ38430022-E0C19242-488F-400D-AD64-9FF3696C1446Q38793914-C246FC3A-699A-4ABF-A9CA-F3003172A028Q39172385-7EA305BD-9A3C-410F-A930-31EB93A1F6EBQ39175612-6B03503F-7666-4DF9-BE80-24588F891F4CQ40382529-1FE0F416-D481-4BCF-9BF4-0F3C4079A0DCQ41633495-7B5E4F40-87B5-44C2-AEBD-E5B8102ABC3EQ41941867-0337D718-1568-4602-89F6-8FC7930F48A9Q43204821-FC1B7768-CE50-405C-94F2-547F41FBA2BEQ49230306-E005E004-18B6-4A50-BE08-25EAA999C332Q57988151-E344F2E8-EA2E-4931-AD56-70A2F69A156D
P2860
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Adverse cardiovascular events ...... view of observational studies.
@ast
Adverse cardiovascular events ...... view of observational studies.
@en
type
label
Adverse cardiovascular events ...... view of observational studies.
@ast
Adverse cardiovascular events ...... view of observational studies.
@en
prefLabel
Adverse cardiovascular events ...... view of observational studies.
@ast
Adverse cardiovascular events ...... view of observational studies.
@en
P2093
P2860
P50
P356
P1433
P1476
Adverse cardiovascular events ...... eview of observational studies
@en
P2093
R D'Alessandro
P2860
P304
P356
10.1177/0333102414550416
P407
P577
2014-09-22T00:00:00Z